Caladrius Biosciences Inc. (NASDAQ:CLBS), with its own contract manufacturing operation, presents a low-risk investment opportunity to enter the immunotherapy space, with the cost and risk of the company's immunotherapy product pipeline offset by manufacturing. Is this below-the-radar biotech company all that it seems?
There are some technology and financial risks involved, and the stock has yet to confirm a short-term upwards bias in trading, but it has broken out of a long-term downtrend. The company reverse split the stock last July 10:1, which, along with large insider ownership, means a small float, while short trading is now at normal volume.
